Targeting neddylation in cancer therapy

Future Oncology

Volumn 8, Issue 11, 2012, Pages 1461-1470

  Duncan, Kristal ^a   Schäfer, Georgia ^b   Vava, Akhona ^a   Parker, M Iqbal ^a   Zerbini, Luiz F ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

cancer; neddylation; ubiquitination

Indexed keywords

[4 [4 [(2,3 DIHYDRO 1H INDEN 1 YL)AMINO] 7H PYRROLO[2,3 D]PYRIMIDIN 7 YL] 2 HYDROXYCYCLOPENTYLMETHYL] SULFAMATE; BORTEZOMIB; CARFILZOMIB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; NEDD8 PROTEIN; REACTIVE OXYGEN METABOLITE; SALINOSPORAMIDE A; UBIQUITIN PROTEIN LIGASE E3; VON HIPPEL LINDAU PROTEIN;

CANCER CELL; CANCER PROGNOSIS; CANCER THERAPY; CARCINOGENESIS; CELL DEDIFFERENTIATION; CELL PROLIFERATION; CELLS; COLON CANCER; DIGESTIVE SYSTEM CANCER; ENZYME ACTIVITY; ENZYME SPECIFICITY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; HUMAN; LARGE CELL LYMPHOMA; LIVER CELL CARCINOMA; MANTLE CELL LYMPHOMA; MULTIPLE MYELOMA; NEDDYLATION; NONHUMAN; PANCREAS CANCER; PHOTOMORPHOGENESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW; TRANSCRIPTION INITIATION; TUMOR SUPPRESSOR GENE; UBIQUITINATION;

ANTINEOPLASTIC AGENTS; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; SIGNAL TRANSDUCTION; UBIQUITIN-PROTEIN LIGASES; UBIQUITINATION;

EID: 84869163764     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.12.131     Document Type: Review

References (83)

1. Adams J. The proteasome: Structure, function, and role in the cell. Cancer Treat. Rev. 29(Suppl. 1), S3-S9 (2003).
2. Kraft C, Peter M, Hofmann K. Selective autophagy: Ubiquitin-mediated recognition and beyond. Nat. Cell Biol. 12(9), 836-841 (2010).
3. Korolchuk VI, Menzies FM, Rubinsztein DC. A novel link between autophagy and the ubiquitin-proteasome system. Autophagy 5(6), 862-863 (2009).
4. Haas AL, Warms JV, Hershko A, Rose IA. Ubiquitin-activating enzyme. Mechanism and role in protein-ubiquitin conjugation. J. Biol. Chem. 257(5), 2543-2548 (1982).
5. Ciechanover A, Elias S, Heller H, Hershko A. 'Covalent affinity' purification of ubiquitin-activating enzyme. J. Biol. Chem. 257(5), 2537-2542 (1982).
6. Groettrup M, Pelzer C, Schmidtke G, Hofmann K. Activating the ubiquitin family: UBA6 challenges the field. Trends Biochem. Sci. 33(5), 230-237 (2008).
7. Pickart CM, Rose IA. Functional heterogeneity of ubiquitin carrier proteins. J. Biol. Chem. 260(3), 1573-1581 (1985). (Pubitemid 15144177)
8. Jentsch S, Seufert W, Sommer T, Reins HA. Ubiquitin-conjugating enzymes: novel regulators of eukaryotic cells. Trends Biochem. Sci. 15(5), 195-198 (1990). (Pubitemid 20190928)
9. Myung J, Kim KB, Crews CM. The ubiquitin-proteasome pathway and proteasome inhibitors. Med. Res. Rev. 21(4), 245-273 (2001). (Pubitemid 32565494)
10. Ciechanover A, Heller H, Elias S, Haas AL, Hershko A. ATP-dependent conjugation of reticulocyte proteins with the polypeptide required for protein degradation. Proc. Natl Acad. Sci. USA 77(3), 1365-1368 (1980).
11. Hatakeyama S, Yada M, Matsumoto M, Ishida N, Nakayama KI. U box proteins as a new family of ubiquitin-protein ligases. J. Biol. Chem. 276(35), 33111-33120 (2001).
12. Huibregtse JM, Scheffner M, Beaudenon S, Howley PM. A family of proteins structurally and functionally related to the E6-AP ubiquitin-protein ligase. Proc. Natl Acad. Sci. USA 92(7), 2563-2567 (1995).
13. Bailly V, Lauder S, Prakash S, Prakash L. Yeast DNA repair proteins Rad6 and Rad18 form a heterodimer that has ubiquitin conjugating, DNA binding, and ATP hydrolytic activities. J. Biol. Chem. 272(37), 23360-23365 (1997). (Pubitemid 27392476)
14. Kamura T, Conrad MN, Yan Q, Conaway RC, Conaway JW. The Rbx1 subunit of SCF and VHL E3 ubiquitin ligase activates Rub1 modification of cullins Cdc53 and Cul2. Genes. Dev. 13(22), 2928-2933 (1999).
15. Mani A, Gelmann EP. The ubiquitin-proteasome pathway and its role in cancer. J. Clin. Oncol. 23(21), 4776-4789 (2005). (Pubitemid 46224082)
16. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63(6), 1129-1136 (1990). (Pubitemid 120035062)
17. Sun Y. E3 ubiquitin ligases as cancer targets and biomarkers. Neoplasia 8(8), 645-654 (2006). (Pubitemid 44379791)
18. Ohta T, Fukuda M. Ubiquitin and breast cancer. Oncogene 23(11), 2079-2088 (2004). (Pubitemid 38496737)
19. Clifford SC, Cockman ME, Smallwood AC et al. Contrasting effects on HIF-1a regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease. Hum. Mol. Genet. 10(10), 1029-1038 (2001). (Pubitemid 32447780)
20. Fukuchi M, Fukai Y, Masuda N et al. High-level expression of the Smad ubiquitin ligase Smurf2 correlates with poor prognosis in patients with esophageal squamous cell carcinoma. Cancer Res. 62(24), 7162-7165 (2002). (Pubitemid 36025230)
21. Kurashige J, Watanabe M, Iwatsuki M et al. Overexpression of microRNA-223 regulates the ubiquitin ligase FBXW7 in oesophageal squamous cell carcinoma. Br. J. Cancer 106(1), 182-188 (2012).
22. Easwaran V, Song V, Polakis P, Byers S. The ubiquitin-proteasome pathway and serine kinase activity modulate adenomatous polyposis coli protein-mediated regulation of b-catenin-lymphocyte enhancer-binding factor signaling. J. Biol. Chem. 274(23), 16641-16645 (1999).
23. Burger AM, Seth AK. The ubiquitin-mediated protein degradation pathway in cancer: Therapeutic implications. Eur. J. Cancer 40(15), 2217-2229 (2004). (Pubitemid 39348871)
24. Pei XY, Dai Y, Grant S. The proteasome inhibitor bortezomib promotes mitochondrial injury and apoptosis induced by the small molecule Bcl-2 inhibitor HA14-1 in multiple myeloma cells. Leukemia 17(10), 2036-2045 (2003). (Pubitemid 37322135)
25. Almond JB, Cohen GM. The proteasome: A novel target for cancer chemotherapy. Leukemia 16(4), 433-443 (2002). (Pubitemid 34449723)
26. Mujtaba T, Dou QP. Advances in the understanding of mechanisms and therapeutic use of bortezomib. Discov. Med. 12(67), 471-480 (2011).
27. Richardson PG, Mitsiades C, Hideshima T, Anderson KC. Bortezomib: Proteasome inhibition as an effective anticancer therapy. Annu. Rev. Med. 57, 33-47 (2006). (Pubitemid 43261977)
28. Richardson PG, Barlogie B, Berenson J et al. A Phase 2 study of bortezomib in relapsed, refractory myeloma. N. Engl. J. Med. 348(26), 2609-2617 (2003). (Pubitemid 36741588)
29. Adams J. Development of the proteasome inhibitor PS-341. Oncologist 7(1), 9-16 (2002). (Pubitemid 34151104)
30. Adams J. The development of proteasome inhibitors as anticancer drugs. Cancer Cell 5(5), 417-421 (2004). (Pubitemid 38610244)
31. Sunwoo JB, Chen Z, Dong G et al. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kB, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin. Cancer Res. 7(5), 1419-1428 (2001). (Pubitemid 32708698)
32. Ling YH, Liebes L, Jiang JD et al. Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines. Clin. Cancer Res. 9(3), 1145-1154 (2003). (Pubitemid 36323724)
33. Chen D, Frezza M, Schmitt S, Kanwar J, Dou QP. Bortezomib as the first proteasome inhibitor anticancer drug: Current status and future perspectives. Curr. Cancer Drug Targets 11(3), 239-253 (2011).
34. Secchiero P, Bosco R, Celeghini C, Zauli G. Recent advances in the therapeutic perspectives of Nutlin-3. Curr. Pharm. Des. 17(6), 569-577 (2011).
35. Baselga J, Tripathy D, Mendelsohn J et al. Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer. Semin. Oncol. 26(4 Suppl. 12), S78-S83 (1999).
36. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344(11), 783-792 (2001). (Pubitemid 32222155)
37. Kumar S, Tomooka Y, Noda M. Identification of a set of genes with developmentally down-regulated expression in the mouse brain. Biochem. Biophys. Res. Commun. 185(3), 1155-1161 (1992).
38. Kumar S, Yoshida Y, Noda M. Cloning of a cDNA which encodes a novel ubiquitin-like protein. Biochem. Biophys. Res. Commun. 195(1), 393-399 (1993). (Pubitemid 23266543)
39. Kamitani T, Kito K, Nguyen HP, Yeh ET. Characterization of NEDD8, a developmentally down-regulated ubiquitin-like protein. J. Biol. Chem. 272(45), 28557-28562 (1997). (Pubitemid 27517807)
40. Gong L, Yeh ET. Identification of the activating and conjugating enzymes of the NEDD8 conjugation pathway. J. Biol. Chem. 274(17), 12036-12042 (1999).
41. Huang DT, Hunt HW, Zhuang M, Ohi MD, Holton JM, Schulman BA. Basis for a ubiquitin-like protein thioester switch toggling E1-E2 affinity. Nature 445(7126), 394-398 (2007). (Pubitemid 46160903)
42. Hori T, Osaka F, Chiba T et al. Covalent modification of all members of human cullin family proteins by NEDD8. Oncogene 18(48), 6829-6834 (1999).
43. Liakopoulos D, Busgen T, Brychzy A, Jentsch S, Pause A. Conjugation of the ubiquitin-like protein NEDD8 to cullin-2 is linked to von Hippel-Lindau tumor suppressor function. Proc. Natl Acad. Sci. USA 96(10), 5510-5515 (1999). (Pubitemid 29234648)
44. Zheng J, Yang X, Harrell JM et al. CAND1 binds to unneddylated CUL1 and regulates the formation of SCF ubiquitin E3 ligase complex. Mol. Cell 10(6), 1519-1526 (2002). (Pubitemid 36050892)
45. Goldenberg SJ, Cascio TC, Shumway SD et al. Structure of the Cand1-Cul1-Roc1 complex reveals regulatory mechanisms for the assembly of the multisubunit cullin-dependent ubiquitin ligases. Cell 119(4), 517-528 (2004). (Pubitemid 39482351)
46. Wu K, Chen A, Pan ZQ. Conjugation of Nedd8 to CUL1 enhances the ability of the ROC1-CUL1 complex to promote ubiquitin polymerization. J. Biol. Chem. 275(41), 32317-32324 (2000).
47. Chamovitz DA, Wei N, Osterlund MT et al. The COP9 complex, a novel multisubunit nuclear regulator involved in light control of a plant developmental switch. Cell 86(1), 115-121 (1996). (Pubitemid 26256583)
48. Seeger M, Kraft R, Ferrell K et al. A novel protein complex involved in signal transduction possessing similarities to 26S proteasome subunits. FASEB J. 12(6), 469-478 (1998). (Pubitemid 28146526)
49. Wei N, Tsuge T, Serino G et al. The COP9 complex is conserved between plants and mammals and is related to the 26S proteasome regulatory complex. Curr. Biol. 8(16), 919-922 (1998). (Pubitemid 28371757)
50. Deng XW, Dubiel W, Wei N, Hofmann K, Mundt K. Unified nomenclature for the COP9 signalosome and its subunits: An essential regulator of development. Trends Genet. 16(7), 289 (2000). (Pubitemid 30389594)
51. Cope GA, Suh GS, Aravind L et al. Role of predicted metalloprotease motif of Jab1/Csn5 in cleavage of Nedd8 from Cul1. Science 298(5593), 608-611 (2002). (Pubitemid 35215316)
52. Lyapina S, Cope G, Shevchenko A et al. Promotion of NEDD-CUL1 conjugate cleavage by COP9 signalosome. Science 292(5520), 1382-1385 (2001). (Pubitemid 32476226)
53. Schwechheimer C, Serino G, Callis J et al. Interactions of the COP9 signalosome with the E3 ubiquitin ligase SCFTIRI in mediating auxin response. Science 292(5520), 1379-1382 (2001). (Pubitemid 32476225)
54. Yang X, Menon S, Lykke-Andersen K et al. The COP9 signalosome inhibits p27(kip1) degradation and impedes G1-S phase progression via deneddylation of SCF Cul1. Curr. Biol. 12(8), 667-672 (2002). (Pubitemid 34315852)
55. Gan-Erdene T, Nagamalleswari K, Yin L, Wu K, Pan ZQ, Wilkinson KD. Identification and characterization of DEN1, a deneddylase of the ULP family. J. Biol. Chem. 278(31), 28892-28900 (2003). (Pubitemid 36939149)
56. Wu K, Yamoah K, Dolios G et al. DEN1 is a dual function protease capable of processing the C terminus of Nedd8 and deconjugating hyper-neddylated CUL1. J. Biol. Chem. 278(31), 28882-28891 (2003). (Pubitemid 36935799)
57. Shen LN, Liu H, Dong C, Xirodimas D, Naismith JH, Hay RT. Structural basis of NEDD8 ubiquitin discrimination by the deNEDDylating enzyme NEDP1. EMBO J. 24(7), 1341-1351 (2005). (Pubitemid 40593055)
58. Mendoza HM, Shen LN, Botting C et al. NEDP1, a highly conserved cysteine protease that deNEDDylates Cullins. J. Biol. Chem. 278(28), 25637-25643 (2003). (Pubitemid 36835317)
59. Chan Y, Yoon J, Wu JT et al. DEN1 deneddylates non-cullin proteins in vivo. J. Cell Sci. 121(Pt 19), 3218-3223 (2008).
60. Leidecker O, Matic I, Mahata B, Pion E, Xirodimas DP. The ubiquitin E1 enzyme Ube1 mediates NEDD8 activation under diverse stress conditions. Cell Cycle 11(6), 1142-1150 (2012).
61. Loftus SJ, Liu G, Carr SM, Munro S, La Thangue NB. NEDDylation regulates E2F-1-dependent transcription. EMBO Rep. 13(9), 811-818. (2012).
62. Oved S, Mosesson Y, Zwang Y et al. Conjugation to Nedd8 instigates ubiquitylation and down-regulation of activated receptor tyrosine kinases. J. Biol. Chem. 281(31), 21640-21651 (2006). (Pubitemid 44181867)
63. Um JW, Han KA, Im E, Oh Y, Lee K, Chung KC. Neddylation positively regulates the ubiquitin E3 ligase activity of parkin. J. Neurosci. Res. 90(5), 1030-1042 (2012).
64. Choo YS, Vogler G, Wang D et al. Regulation of parkin and PINK1 by neddylation. Hum. Mol. Genet. 21(11), 2514-2523 (2012).
65. Leung SK, Ohh M. Playing tag with HIF: The VHL story. J. Biomed. Biotechnol. 2(3), 131-135 (2002). (Pubitemid 44204509)
66. Ohh M, Kaelin WG Jr. VHL and kidney cancer. Methods Mol. Biol. 222, 167-183 (2003).
67. Salon C, Brambilla E, Brambilla C, Lantuejoul S, Gazzeri S, Eymin B. Altered pattern of Cul-1 protein expression and neddylation in human lung tumours: Relationships with CAND1 and cyclin E protein levels. J. Pathol. 213(3), 303-310 (2007). (Pubitemid 350074020)
68. Kim AY, Bommelje CC, Lee BE et al. SCCRO (DCUN1D1) is an essential component of the E3 complex for neddylation. J. Biol. Chem. 283(48), 33211-33220 (2008).
69. Sarkaria I, O-charoenrat P, Talbot SG et al. Squamous cell carcinoma related oncogene/ DCUN1D1 is highly conserved and activated by amplification in squamous cell carcinomas. Cancer Res. 66(19), 9437-9444 (2006). (Pubitemid 44623640)
70. Kubbutat MH, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. Nature 387(6630), 299-303 (1997). (Pubitemid 27220767)
71. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature 387(6630), 296-299 (1997). (Pubitemid 27220766)
72. Honda R, Yasuda H. Activity of MDM2, a ubiquitin ligase, toward p53 or itself is dependent on the RING finger domain of the ligase. Oncogene 19(11), 1473-1476 (2000). (Pubitemid 30171179)
73. Xirodimas DP, Saville MK, Bourdon JC, Hay RT, Lane DP. Mdm2-mediated NEDD8 conjugation of p53 inhibits its transcriptional activity. Cell 118(1), 83-97 (2004). (Pubitemid 38902816)
74. Embade N, Fernandez-Ramos D, Varela-Rey M et al. Murine double minute 2 regulates Hu antigen R stability in human liver and colon cancer through NEDDylation. Hepatology 55(4), 1237-1248 (2012).
75. Noguchi K, Okumura F, Takahashi N et al. TRIM40 promotes neddylation of IKKg and is downregulated in gastrointestinal cancers. Carcinogenesis 32(7), 995-1004 (2011).
76. Amir RE, Iwai K, Ciechanover A. The NEDD8 pathway is essential for SCF(b- TrCP)-mediated ubiquitination and processing of the NF-kB precursor p105. J. Biol. Chem. 277(26), 23253-23259 (2002). (Pubitemid 34952153)
77. Soucy TA, Smith PG, Milhollen MA et al. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature 458(7239), 732-736 (2009).
78. Brownell JE, Sintchak MD, Gavin JM et al. Substrate-assisted inhibition of ubiquitin-like protein-activating enzymes: The NEDD8 E1 inhibitor MLN4924 forms a NEDD8-AMP mimetic in situ. Mol. Cell 37(1), 102-111 (2011).
79. Swords RT, Kelly KR, Smith PG et al. Inhibition of NEDD8-activating enzyme: A novel approach for the treatment of acute myeloid leukemia. Blood 115(18), 3796-3800 (2010).
80. Milhollen MA, Traore T, Adams-Duffy J et al. MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: Rationale for treatment of NF-kB-dependent lymphoma. Blood 116(9), 1515-1523 (2010).
81. Jia L, Li H, Sun Y. Induction of p21- dependent senescence by an NAE inhibitor, MLN4924, as a mechanism of growth suppression. Neoplasia 13(6), 561-569 (2011).
82. Tan M, Li Y, Yang R, Xi N, Sun Y. Inactivation of SAG E3 ubiquitin ligase blocks embryonic stem cell differentiation and sensitizes leukemia cells to retinoid acid. PLoS ONE 6(11), E27726 (2011).
83. Wei D, Li H, Yu J et al. Radiosensitization of human pancreatic cancer cells by MLN4924, an investigational NEDD8-activating enzyme inhibitor. Cancer Res. 72(1), 282-293 (2012).